Drug screening Tag

Ultrafast and Scalable CAR-T Manufacturing Using Microfluidics

Chimeric antigen receptor T-cell (CAR-T) therapy has reshaped the treatment landscape for hematologic cancers, but the process of manufacturing CAR-T cells remains a major bottleneck. Traditional protocols might stretch over 9 days and risk shifting T-cell populations toward terminally differentiated phenotypes, depleting the naive-like...